
(LSE: PEY/PEYS)
Partners Group Private Equity Limited
NAV declined by 0.7% in August
· NAV decreased to EUR 13.80 per share, corresponding to EUR 954.1 million
· Value creation (+0.7%) offset by unfavorable currency movements (-1.0%)
· PGPE Ltd received EUR 14.2 million in distributions and invested EUR 3.2 million during the month
The NAV of PGPE Ltd closed in August at EUR 13.80 per share. The underlying portfolio delivered solid value creation of 0.7%, though this was offset by currency headwinds primarily as the US Dollar weakened 2.2% against the Euro during the month, negatively impacting NAV by 1.0% and resulting in a total return decline of 0.7%
Over the same period, PGPE Ltd received EUR 14.2 million in distributions, of which EUR 9.3 million stemmed from the exit of its investment in Global Blue, a provider of VAT refund and foreign exchange services for international travelers. In February this year, the company announced that it had entered into a definitive agreement under which Shift4, an integrated payments and commerce technology provider, would acquire the business in an all-cash transaction, valued at approximately USD 2.5 billion (enterprise value). The transaction was finalized recently. Following the acquisition, Global Blue will be delisted from the NYSE. Partners Group, on behalf of its clients, originally invested in Global Blue in 2012 and listed the company on the NYSE in 2020, subsequently selling down a portion of its holding.
EUR 4.5 million came from a further sale of shares of Galderma, a pure-play dermatology category leader. As of 31 August 2025, the remaining NAV of Galderma in the portfolio of PGPE Ltd is EUR 23.8 million. Recently, Galderma released its financial report for the first half of 2025, which showed record net sales of over USD 2 billion and 12.2% year-on-year growth on constant currency terms. This was driven by volume growth and a favorable change in sales mix. Meanwhile, new product launches showed significant progress.
Finally, PGPE Ltd invested EUR 1.6 million in restor3d, a technology-driven orthopedic solutions specialist in the US. Founded in 2017, restor3d offers a full portfolio of implants across shoulder, hip, knee, foot, and ankle, and combines proprietary AI-driven design software, vertically integrated manufacturing, and rapid surgical planning. In 2024, restor3d partnered with more than 520 surgeons across 740 hospitals nationwide.
Ends.
About Partners Group Private Equity Limited
PGPE Ltd is an investment holding company founded in 1999 and domiciled in Guernsey. It invests in private equity direct investments. PGPE Ltd is managed in its investment activities by Partners Group, a global private markets investment management firm with over USD 174 billion in investment programs under management in private markets, of which USD 83 billion is in private equity. Partners Group itself is listed on the Swiss Stock Exchange (ticker: PGHN). PGPE Ltd aims to provide shareholders with long-term capital growth and an attractive dividend yield. PGPE Ltd is traded on the Main Market of the London Stock Exchange (ticker: PEY for the Euro quote; PEYS for the Sterling quote).
Contacts
Partners Group Private Equity Limited:
pgpe-ltd@partnersgroup.com
www.partnersgroupprivateequitylimited.com
Investor relations contact: Andreea Mateescu Phone: +41 41 784 66 73 E-mail: andreea.mateescu@partnersgroup.com
| Media relations contact: Jenny Blinch Phone: +41 41 784 65 26 E-mail: jenny.blinch@partnersgroup.com |
Registered Number: 35241 LEI: 54930038LU8RDPFFVJ57
Notes:
1. Note that references in this announcement to Partners Group Private Equity Limited have been abbreviated to "PGPE Ltd" or "the Company". References to Partners Group AG have been abbreviated to "Partners Group" or "the Investment Manager".
2. This document does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities and neither is it intended to be an investment advertisement or sales instrument of Partners Group Private Equity Limited. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes must inform themselves about and observe any such restrictions on the distribution of this document. In particular, this document and the information contained therein are not for distribution or publication, neither directly nor indirectly, in or into the United States of America, Canada, Australia or Japan.
3. This document may have been prepared using financial information contained in the books and records of the product described herein as of the reporting date. This information is believed to be accurate but has not been audited by any third party. This document may describe past performance, which may not be indicative of future results. No liability is accepted for any actions taken on the basis of the information provided in this document. Neither the contents of PGPE Ltd's website nor the contents of any website accessible from hyperlinks on PGPE Ltd's website (or any other website) are incorporated into, or form part of, this announcement.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.